Work

721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study

Year: 2021

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.1164

Authors: N. Colombo, D.D. Nguyen, G.F. Fleming, R.N. Grisham, D. Lorusso, T. Van Gorp, A. Oaknin, H.I. Pashova, A. Grauer

Institutions: European Institute of Oncology, University of Milano-Bicocca, Corcept Therapeutics (United States), University of Chicago, University of Chicago Medical Center, Memorial Sloan Kettering Cancer Center, Agostino Gemelli University Polyclinic, Universitair Ziekenhuis Leuven, KU Leuven, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3204040372

FWCI: 1.198

Cites:

Cited by: 12

Related to: 10